Literature DB >> 26808131

A New Hitherto Unreported Histopathologic Manifestation of Mammary Analogue Secretory Carcinoma: "Masked MASC" Associated With Low-grade Mucinous Adenocarcinoma and Low-grade In Situ Carcinoma Components.

Fredrik Petersson1, Michael Michal, Dmitry V Kazakov, Petr Grossmann, Michal Michal.   

Abstract

We present a salivary gland tumor of the parotid gland in a 54-year-old woman, which contained a minor mammary analogue secretory carcinoma (MASC) component (20%) intermixed with a morphologically entirely different mucinous adenocarcinomatous component that comprised 80% of the tumor mass and a morphologically nondescript low-grade intraductal carcinoma (in situ) component. On fluorescence in situ hybridization, a break in the ETV6 gene was documented in the mucinous adenocarcinomatous, the conventional MASC, and the intraductal (in situ) components. RT-PCR failed to reveal an ETV6-NTRK3 fusion. The entire conventional MASC and only rare mucinous adenocarcinoma tumor cells were mammaglobin positive, whereas the low-grade intraductal carcinoma (in-situ) component was negative. S-100 protein stained only the MASC component.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26808131     DOI: 10.1097/PAI.0000000000000320

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  2 in total

1.  High-grade Salivary Gland Adenocarcinoma Harboring ETV6-NTRK3 Fusion: Defined by Morphology or Molecular Aberration?

Authors:  Niels J Rupp; Constanze Nemes; Elisabeth J Rushing; Gerhard F Huber; Sandra N Freiberger
Journal:  Head Neck Pathol       Date:  2021-02-05

2.  Mammary analogue secretory carcinoma of salivary glands: diagnostic pitfall with distinct immunohistochemical profile and molecular features.

Authors:  Oliver Bissinger; Carolin Götz; Andreas Kolk; Henning A Bier; Abbas Agaimy; Henning Frenzel; Sven Perner; Julika Ribbat-Idel; Klaus Dietrich Wolff; Wilko Weichert; Caroline Mogler
Journal:  Rare Tumors       Date:  2017-10-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.